新型冠状病毒疫苗诱发甲状腺疾病：挑战与应对

doi:10.16138/j.1673-6087.2023.02.012

摘要/Abstract

关键词: 冠状病毒病2019, 甲状腺疾病, 佐剂, 疫苗, 接种

中图分类号:

R581

袁力, 相萍萍, 陈国芳, 徐书杭, 刘超. 新型冠状病毒疫苗诱发甲状腺疾病：挑战与应对[J]. 内科理论与实践, 2023, 18(02): 121-123.

YUAN Li, XIANG Pingping, CHEN Guofang, et al . COVID-19 vaccine induced thyroid disease: challenges and strategies[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(02): 121-123.

图/表 1

表1

参考文献 25

[1]	Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission[J]. Lancet, 2020, 395(10223): 514-523. doi: 10.1016/S0140-6736(20)30154-9 URL
[2]	Ferreira LN, Pereira LN, da Fé Brás M, et al. Quality of life under the COVID-19 quarantine[J]. Qual Life Res, 2021, 30(5): 1389-1405. doi: 10.1007/s11136-020-02724-x pmid: 33389523
[3]	Saeed S, Awasthi AA, Nandi D, et al. Knowledge, attitude and practice towards COVID-19 among individuals with associated comorbidities[J]. J Med Life, 2021, 14(2): 225-237. doi: 10.25122/jml-2020-0184 pmid: 34104246
[4]	Li MY, Li L, Zhang Y, et al. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues[J]. Infect Dis Poverty, 2020, 9(1): 45. doi: 10.1186/s40249-020-00662-x
[5]	Lui DTW, Lee CH, Chow WS, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19[J]. J Clin Endocrinol Metab, 2021, 106(2): e926-e935. doi: 10.1210/clinem/dgaa813 pmid: 33141191
[6]	Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19[J]. J Endocrinol Invest, 2020, 43(10): 1527-1528. doi: 10.1007/s40618-020-01366-7 pmid: 32686042
[7]	Jiménez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: a cause of recurrent Graves’ hyperthyroidism?[J]. J Endocrinol Invest, 2021, 44(2): 387-388. doi: 10.1007/s40618-020-01440-0 pmid: 33025554
[8]	Montebello A. Recurrent Graves’ disease post SARS-CoV-2 infection[J]. BMJ Case Rep, 2021, 14(8): e244714. doi: 10.1136/bcr-2021-244714 URL
[9]	Pastor S, Molina á Sr, De Celis E. Thyrotoxic crisis and COVID-19 infection[J]. Cureus, 2020, 12(11): e11305.
[10]	Iremli BG, Şendur SN, Ünlütürk U. Three cases of sub-acute thyroiditis following SARS-CoV-2 vaccine[J]. J Clin Endocrinol Metab, 2021, 106(9): 2600-2605. doi: 10.1210/clinem/dgab373 URL
[11]	Sahin Tekin M, Şaylısoy S, Yorulmaz G. Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report[J]. Hum Vaccin Immunother, 2021, 17(11): 4090-4092. doi: 10.1080/21645515.2021.1947102 URL
[12]	Oğuz SH, Şendur SN, Iremli BG, et al. SARS-CoV-2 vaccine-induced thyroiditis: safety of revaccinations and clinical follow-up[J]. J Clin Endocrinol Metab, 2022, 107(5): e1823-e1834. doi: 10.1210/clinem/dgac049 URL
[13]	Schimmel J, Alba EL, Chen A, et al. Letter to the editor: thyroiditis and thyrotoxicosis after the SARS-CoV-2 mRNA vaccine[J]. Thyroid, 2021, 31(9): 1440. doi: 10.1089/thy.2021.0184 URL
[14]	Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two cases of Graves’ disease following SARS-CoV-2 vaccination[J]. Thyroid, 2021, 31(9): 1436-1439. doi: 10.1089/thy.2021.0142 pmid: 33858208
[15]	Bornemann C, Woyk K, Bouter C. Case report: two cases of subacute thyroiditis following SARS-CoV-2 vaccination[J]. Front Med (Lausanne), 2021, 8: 737142.
[16]	Raashid S, Khan O, Rehman Z, et al. Subacute thyroiditis after receiving inactivated virus vaccine for COVID-19[J]. J Community Hosp Intern Med Perspect, 2022, 12(2):14-17.
[17]	Zettinig G, Krebs M. Two further cases of Graves’ disease following SARS-Cov-2 vaccination[J]. J Endocrinol Invest, 2022, 45(1):227-228. doi: 10.1007/s40618-021-01650-0
[18]	Oğuz SH, Şendur SN, Iremli BG, et al. SARS-CoV-2 vaccine-induced thyroiditis: safety of revaccinations and clinical follow-up[J]. J Clin Endocrinol Metab, 2022, 107(5): e1823-e1834. doi: 10.1210/clinem/dgac049 URL
[19]	Chattopadhyay S, Chen JY, Chen HW, et al. Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation[J]. Nanotheranostics, 2017, 1(3): 244-260. doi: 10.7150/ntno.19796 pmid: 29071191
[20]	Vartak A, Sucheck SJ. Recent advances in subunit vaccine carriers[J]. Vaccines (Basel), 2016, 4(2): 12.
[21]	Tenforde MW, Self WH, Naioti EA, et al. Sustained effectiveness of pfizer-bioNTech and moderna vaccines against COVID-19 associated hospitalizations among adults[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(34): 1156-1162. doi: 10.15585/mmwr.mm7034e2 URL
[22]	Watad A, David P, Brown S, et al. Autoimmune/inflammatory syndrome induced by adjuvants and thyroid autoimmunity[J]. Front Endocrinol (Lausanne), 2017, 7: 150.
[23]	Jara LJ, García-Collinot G, Medina G, et al. Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld’s syndrome)[J]. Immunol Res, 2017, 65(1): 8-16. doi: 10.1007/s12026-016-8811-0 URL
[24]	Bragazzi NL, Hejly A, Watad A, et al. ASIA syndrome and endocrine autoimmune disorders[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1): 101412. doi: 10.1016/j.beem.2020.101412 URL
[25]	Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens[J]. Front Immunol, 2021, 11: 617089. doi: 10.3389/fimmu.2020.617089 URL

SARS-CoV-2抗原	SARS-CoV-2序列	映射区间	TPO序列	ID（%）
Chain A, Helicase	VLTSHT-VM	226~233	VL-SVTLVM^*	67
Chain A, Spike protein S1, S2	VLGQSKR-VD	1 020~1 028	VLEESKRLVD^*	70
Chain B, Replicase polyprotein 1a	EDKRAKVTSAM-QTM	2~5	ESKRL-VDTAMYATM^*	53
Chain A, Spike gycoprotein	NLTTRTQLPPA	48~58	NLKKRGILSPA^*	55
Chain A, nsp16	APGTAVLRQWLP	79~90	ASNTALAR-WLP^*	58
Chain A, Spike protein S1, S2	VTWFHAIHVS	49~58	VTR-HVIQVS^*	60
Chain A, Replicase polyprotein 1ab	SAARLTPCGTG	6~16	SAA-CGTG^*	64
Chain A, Replicase polyprotein 1a	LLSVLQQLR	13~21	LLRVHARLR^*	56
Chain A, Spike glycoprotein	FL-GRSLEV	1 221~1 228	FLAGDGRASEV	55
Chain A, nsp3	ADIV-EEAKKV	21~30	ADAVYQEARKV^*	64
Chain A, Main protease	LNGLWLDDTVY	27~37	LNAHWSADAVY^*	55
Chain A, Nucleoprotein	PY-G-AN	77~81	PYEGYDSTAN^*	50
Chain A, Spike glycoprotein	WVLLSTFLGRSGGGL	1 219~1 233	WTLL-R-GGGL	53
Chain A, Spike glycoprotein	VLYNSASFST	34~43	VLSNS-ST	60
Chain A, Uridylate-specific endoribonuclease	SSGVDLGTENL	8~18	SSTLDLASINL	55
Chain A, Uridylate-specific endoribonuclease	TENLYFQSNMS	15~25	TERLFVLSNSS	55
Chain A, 2’-O-methyltransferase	FV-SDADSTL	105~113	FVLSNS-STL^*	60
Chain A, Helicase	LSYGIATVREV	147~1 578	LSTAIAS-RSV^*	55
Chain A, Spike protein S1, S2	PD-VD-LG	86~91	PDNIDVWLG	56
Chain B, nsp3	RARAGEAANF-CALI	138~151	RARTG-PLFAC-LI^*	53
Chain A, Spike glycoprotein	YEQSSRENL	1 237~1 245	YELQGREQL^*	67
Chain A, Spike glycoprotein	YKLPDDFTG-CV	90~100	YELGDD-GRTCV^*	54
Chain A, 3C-like proteinase	ELLQNGMNGRT	268~278	EL-GDDGRT^*	55
S protein in complex bound with 4A8	SPRRARSVASQ	671~681	SPQRA-AAQ^*	55

新型冠状病毒疫苗诱发甲状腺疾病：挑战与应对

COVID-19 vaccine induced thyroid disease: challenges and strategies

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	相萍萍, 刘超. 新型冠状病毒感染：甲状腺疾病的新挑战[J]. 内科理论与实践, 2022, 17(06): 486-490.
[2]	石峰, 郭竹英, 郭海艳. 新型冠状病毒肺炎患者外周血淋巴细胞亚群变化的临床意义[J]. 诊断学理论与实践, 2022, 21(05): 619-624.
[3]	宗春燕，沈键锋. 免疫治疗能否治愈肿瘤？[J]. 上海交通大学学报, 2021, 55(Sup.1): 53-54.
[4]	郑蕾, 张世瑜, 严佶祺. 甲状腺外科实施加速康复外科的临床效果[J]. 外科理论与实践, 2020, 25(03): 252-255.
[5]	陆翠, 杨程德,. 风湿病患者疫苗接种的研究进展[J]. 内科理论与实践, 2019, 14(01): 58-62.
[6]	信宁宁;黄宗南;. 基于最短处理时间疫苗的免疫遗传算法优化FJSP问题[J]. 机械设计与研究, 2013, 29(03): 53-55.
[7]	许悦, 邹强, 胡轶红,. 乳腺癌治疗性疫苗临床研究进展[J]. 外科理论与实践, 2012, 17(02): 195-200.
[8]	汪岛, 王曙,. 硒与甲状腺:密不可分的联系[J]. 内科理论与实践, 2011, 6(05): 397-400.
[9]	郁丹燕, 沈立松,. 调节性T细胞亚群与自身免疫性甲状腺疾病发病机制的关系[J]. 诊断学理论与实践, 2011, 10(01): 78-81.
[10]	孙富艳, 张云智, 戴振声, 刘莉, 卢洪洲,. 148名医务人员接种甲型H_1N_1流行性感冒病毒裂解灭活疫苗后的免疫原性和安全性分析[J]. 内科理论与实践, 2010, 5(06): 488-493.
[11]	孙富艳, 卢洪洲,. 2009A/H_1N_1流行性感冒病毒疫苗研究近况[J]. 内科理论与实践, 2010, 5(04): 347-350.
[12]	赵咏桔,. 甲状腺结节良恶性的判断和处理[J]. 内科理论与实践, 2010, 5(02): 130-134.
[13]	刘超, 杨昱, 陈立立,. 甲状腺自身抗体的基础和临床进展[J]. 内科理论与实践, 2010, 5(02): 139-146.
[14]	滕卫平,. 我国甲状腺疾病的研究方向[J]. 内科理论与实践, 2010, 5(02): 109-111.
[15]	滕卫平,. 碘营养与甲状腺疾病[J]. 内科理论与实践, 2010, 5(02): 112-117.